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Abstract
Background: Herpes zoster (HZ) may result in severe complications requiring hospital treatment, particularly in
patients with comorbidity. Nevertheless, data on HZ from nationwide population-based hospital registries are
sparse.
Methods: We conducted a cohort study describing first-time hospital-based (inpatient, outpatient, and emergency
room) HZ diagnoses in the Danish National Patient Registry, 1994–2012. We computed the diagnosis rate;
prevalence of demographic characteristics, comorbidities, and complications; length of hospital stay; and
standardized mortality ratios (SMRs) using the Danish population as reference. We classified comorbidity using
the Charlson Comorbidity Index (CCI) scoring system and categorized patients in groups of no (score 0), moderate
(score 1), severe (score 2), and very severe comorbidity (score ≥3). In addition, we computed the prevalence of
certain conditions associated with immune dysregulation (stem cell or bone marrow transplantation, solid organ
transplantation, HIV infection, primary immunodeficiency, any cancer, and autoimmune diseases).
Results: The diagnosis rate increased almost exponentially from 6 to 91.9 per 100,000 person-years between age
50 and ≥90 years. The age-standardized rate was stable throughout the study period. The median length of hospital
stay was 4 days (interquartile range: 1–8 days) for inpatients with HZ as the main reason for admission. According
to the CCI, 44.3 % of patients had no comorbidity, 17.3 % moderate comorbidity, 17.4 % severe comorbidity, and
21.0 % very severe comorbidity. Comorbidities involving immune dysregulation, such as malignant (21 %) and
autoimmune diseases (17 %), were particularly prevalent. Thirty percent had neurological, ophthalmic, or other
complications. HZ was associated with increased all-cause mortality overall (SMR 1.8, 95 % CI: 1.7–1.8), but not in
analyses restricted to patients without comorbidity (SMR 1.0, 95 % CI: 0.9–1.0).
Conclusions: This study provides estimates of the epidemiology of hospital-based (severe) HZ. The diagnosis rate
increased substantially with age. Complications and comorbidities were prevalent, likely resulting in increased mortality.
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Background
Herpes zoster (HZ) is a neurocutaneous infection caused
by reactivation of the varicella-zoster virus (human her-
pesvirus 3) from the sensory ganglia when cell-mediated
immunity wanes below a critical level [1]. In a review of
data from nine European countries, the overall incidence
rate in the general population was approximately 100–
400 per 100,000 person-years in adults aged 50 years or
younger. Thereafter, it increased notably, reaching 1000
per 100,000 person-years after age 80 years [2]. The risk
of HZ is increased in patients with cell-mediated
immunodeficiency, including that caused by drugs (e.g.,
corticosteroids or chemotherapy), radiotherapy, viral
infections (i.e., human immunodeficiency virus [HIV]),
or malignancy.
HZ may have severe acute complications, such as
meningo-encephalitis and cutaneous dissemination, in
particular among individuals with the aforementioned
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predisposing conditions [3, 4]. These patients are more
likely to be treated in the hospital or in hospital outpatient
specialty clinics. When assessing the epidemiology of HZ,
it is important also to consider these severe or potentially
severe cases diagnosed in a hospital-based setting. Never-
theless, results from nationwide population-based hospital
registries in Europe are sparse concerning the diagnosis
rate and patient characteristics, including prevalence of
complications and comorbidities. In particular, none of
the previous population-based studies published data per-
taining specifically to diagnoses from hospital outpatient
specialty clinics. To address this paucity of data, we
conducted a nationwide Danish cohort study describing
HZ in a hospital-based setting, including diagnosis rate,
patient demographics, severity, comorbidity burden,
length of admission, and subsequent all-cause mortality.
Methods
The Danish National Health Service provides tax-funded
universal health care to all residents (population 5.6
million), guaranteeing unfettered access to general prac-
titioners and hospitals [5]. Utilization of health services
is recorded in nationwide databases using the unique
central personal register (CPR) number assigned to each
Danish resident at birth or immigration [5]. The CPR
number allowed for unambiguous individual-level link-
age of the registries used in the current study.
The Danish National Patient Registry (DNPR) contains
data on all admissions to Danish non-psychiatric depart-
ments since 1977 and visits to hospital-based outpatient
clinics (i.e., ambulatory medical care) and emergency
rooms since 1994 [6]. Each DNPR record contains the
CPR number of the patient, dates of hospital admission
and discharge or start and end of outpatient contact,
information on procedures performed, and diagnoses.
Each record includes a primary diagnosis, i.e., the condi-
tion considered the main reason for the hospital contact.
Diagnoses are assigned by the discharging physician at
the time of hospital discharge or at the end of an out-
patient contact using the International Classification of
Diseases, 8th revision (ICD-8) until the end of 1993 and
10th revision (ICD-10) thereafter [6]. Surgical proce-
dures are coded by the surgeon according to a Danish
classification system (1977 through 1995) and a Danish
version of the Nordic Medico-Statistical Committee
Classification of Surgical Procedures (from 1996 on-
wards). Since 2002, the DNPR has provided the basis for
reimbursing both public and private hospitals. Reporting
of all services provided in the private hospital sector
became mandatory in 2003. General practitioners and
private practice specialists do not report to the DNPR.
Diagnosis codes and definitions used are provided in
Additional file 1: Table S1.
We used the DNPR to identify all first-time inpatient,
outpatient, and emergency room diagnoses of HZ. To
ensure complete information on outpatient and emer-
gency room diagnoses and to avoid potential problems
associated with the transition between the ICD-8 and
ICD-10 coding systems, we chose a study period from
January 1, 1994 to December 31, 2012, when ICD-codes
were used, exclusively. The date of discharge or end of
outpatient contact was considered the diagnosis date.
Based on patients’ first-ever HZ diagnosis recorded in
the DNPR, we classified HZ diagnoses according to type
of hospital-based contact (inpatient, outpatient clinic, or
emergency room) and type of diagnosis (primary or
secondary). We also identified individual ICD-10 codes
for HZ. However, because of the clinical difficulty of
distinguishing between HZ encephalitis and meningitis,
we combined ICD-10 codes B02.0 and B02.1 in our
analysis. Similarly, we grouped ICD-10 codes according to
severity (complicated or uncomplicated) and extent (dis-
seminated or localized), as shown in Additional file 1:
Table S1. The difference between groups of complicated and
disseminated HZ is attributed to codes for HZ ophthalmi-
cus, which is regarded as a localized but complicated form.
To give an overview of reasons for healthcare contacts
among patients with a secondary HZ diagnosis, we cate-
gorized the primary diagnosis according to a list of 203
morbidity groups based on the ICD-8 and ICD-10
World Health Organization morbidity tables. This code
list has been published previously [7] and is outlined in
detail in Additional file 1: Table S1. Additional codes
outside this list comprised general and unspecific rea-
sons for hospital contact. We grouped them into four
categories (‘Symptoms, signs and abnormal clinical and
laboratory findings not otherwise specified’, ‘Injury,
poisoning and certain other consequences of external
causes’, ‘Observation for or follow-up after treatment for
cancer’, and ‘Contact with health services due to solid
organ or bone marrow transplantation, and ‘Other
factors influencing health status and contact with health
services’). The HZ vaccine, which is approved by the
European Medicines Agency for use in adults aged
50 years or older, did not become available in Denmark
until September 2014, and hence not considered in the
present study [8].
To quantify comorbidity, we obtained information on
all primary, secondary, and additional diagnoses re-
corded in the DNPR before or on the same date as the
HZ diagnosis. We classified comorbidity using the
Charlson Comorbidity Index (CCI), a scoring system
that assigns between one and six points to 19 groups of
chronic diseases (Additional file 1: Table S1) according
to their ability to predict death [9]. We obtained infor-
mation on diagnoses in each disease group. Based on the
total CCI score, we also categorized patients into levels
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of none (score 0), moderate (score 1), severe (score 2),
and very severe (score 3 or more) comorbidity. We also
obtained information on diagnosis history of conditions
associated with immune dysregulation (i.e., stem cell or
bone marrow transplantation, solid organ transplant-
ation, HIV infection, primary immunodeficiency, any
cancer, and autoimmune diseases) and thus potentially
an increased HZ risk [1]. For the categories HIV infec-
tion, any cancer, and autoimmune diseases, there was an
overlap with codes included in the CCI.
The Danish Civil Registration System (CRS) provides a
record of changes in vital and migration status for the
entire population since 1968 [5]. We used the CRS to
follow HZ patients from diagnosis until the date of
death, emigration, or December 31, 2012.
Statistical analysis
We computed the annual rate of hospital-based HZ
diagnoses throughout the study period, with direct age
standardization [10] to the 2000 Danish census. We
characterized patients according to age, sex, comorbidi-
ties, calendar period of diagnosis (1994–1999, 2000–
2005, and 2006–2012), and types of HZ diagnoses. For
patients with an inpatient primary HZ diagnosis, we
computed the median and total length of hospital stay.
We used the Kaplan-Meier estimator to compute ab-
solute mortality risks. We computed standardized mor-
tality ratios (SMRs) with 95 % confidence intervals (CIs)
for HZ patients using indirect standardization [10], with
the general Danish population as reference. The ex-
pected number of deaths was obtained by multiplying
the number of person-years at risk in the HZ cohort
with the rate of death in the general population accord-
ing to 5-year age groups, sex, and calendar year. The
SMR was computed as the ratio of the observed to the
expected number of deaths. Corresponding 95 % CIs
were computed assuming that the observed number of
deaths followed a Poisson distribution. We performed
analyses overall and in subgroups of demographic and
patient characteristics.
Analyses were performed using STATA® (version 12.1,
STATA, College Station, TX). The study was approved
by the Danish Data Protection Agency (record number
1–16–02–1–08). Danish legislation does not require
ethical review board approval or informed consent from
subjects in registry-based studies.
Results
Hospital diagnosis rate
We identified 13,663 first-time hospital-based diagnoses
of HZ in Denmark between 1994 and 2012, corresponding
to a standardized HZ rate of 13.1 (95 % CI: 12.9–13.3) per
100,000 person-years (Table 1). The rate was stable
throughout the study period, both overall (Fig. 1) and in
subgroups defined by age and sex (Additional file 1: Fig-
ures S1 and S2).
The HZ rate varied markedly with age. The rate was
3–6 per 100,000 person-years for persons aged below
50 years after which it increased approximately twofold
with each decade of age, reaching 91.1 per 100,000
person-years for those aged 90 years or older (Table 1).
For all individuals aged 50 years or more (i.e., those po-
tentially eligible for the HZ vaccine), the overall diagno-
sis rate was 30.1 per 100,000 person-years. The increase
in rate with age was observed for all subtypes of HZ
diagnoses, but was most pronounced for inpatient diag-
noses (Fig. 2).
The standardized diagnosis rate was slightly higher
among women than men (13.6 vs. 12.5 per 100,000
person-years). This difference was primarily driven by
a difference in rates for persons aged 50–89 years
(Table 1).
Type of diagnosis, complications, and length of stay
Sixty percent of patients were diagnosed with HZ during
a hospital admission, 25 % in an outpatient clinic, and
15 % in the emergency room (Table 2). The majority of
diagnoses were primary (72 %). Reasons for hospital
contact among patients with secondary HZ diagnoses
are listed in Additional file 1: Table S2; the most fre-
quent were the unspecific codes ‘other factors influen-
cing health status and contact with health services’
(8.1 %) and ‘symptoms, signs, and abnormal clinical and
laboratory findings’ (8.0 %), followed by ‘pneumonia’
(5.9 %), and ‘bronchitis, emphysema and other obstruct-
ive pulmonary diseases’ (4.8 %). In total, cancer was the
primary diagnosis in 9.5 % of patients with a secondary
HZ diagnosis.
Complicated HZ occurred among 30 % of patients, the
most frequent being HZ ophthalmicus followed by
nervous system involvement (Table 2). There was a
slight increase in the incidence and proportion of
patients with ‘HZ encephalitis’, ‘HZ meningitis’ and ‘HZ
with other complication’ during the study period.
Almost half of the outpatient HZ diagnoses were com-
plicated (28 % were HZ ophthalmicus), compared
with one-fourth of inpatient and emergency room
diagnoses (Additional file 1: Table S3).
The median length of stay for inpatients with a pri-
mary HZ diagnosis was 4 days (interquartile range 1–8
days, mean 6.2 days), increasing with age (Table 1). On
average, patients with primary inpatient HZ diagnoses
had an annual total of 1634 inpatient days, of which
88 % were in patients aged 50 years or more. The lon-
gest stays were observed in patients with complicated
HZ, especially HZ encephalitis (median 10 days, inter-
quartile range 6–18 days, mean 15.5 days).
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Comorbidity
A large proportion of persons with HZ had comorbidity.
As measured by the CCI, 44 % had no comorbidity,
17 % had moderate comorbidity, 17 % had severe co-
morbidity, and 21 % had very severe comorbidity (Table
3). The most prevalent diagnoses were autoimmune
diseases (17 %), chronic pulmonary disease (14 %), non-
metastatic solid tumor (13 %), cerebrovascular disease
(11 %), congestive heart failure (7.7 %), connective tissue
disease (7.2 %), myocardial infarction (6.7 %), diabetes
without end-organ damage (6.7 %), ulcer disease (6.2 %),
and lymphoma (6.1 %). In total, 21 % had an active or
previous cancer. Diseases possibly associated with im-
mune dysregulation were recorded in 36 % of HZ pa-
tients. The prevalence of HIV infection was 1.5 %.
Median age and comorbidity burden were highest in
Table 1 Diagnosis rates and median length of stay for hospital-based diagnoses of HZ, Denmark, 1994–2012











0–9 492 12,580,957 3.9 234 6,132,651 3.8 258 6,448,306 4.0 1 (0–3)
10–19 368 12,030,773 3.1 195 5,867,909 3.3 173 6,162,864 2.8 3 (1–6)
20–29 623 13,126,461 4.7 303 6,473,069 4.7 320 6,653,392 4.8 3 (1–6)
30–39 772 14,872,135 5.2 379 7,319,246 5.2 393 7,552,889 5.2 2 (1–5)
40–49 885 14,732,844 6.0 440 7,263,028 6.1 445 7,469,816 6.0 3 (1–6)
50–59 1650 13,516,050 12.2 899 6,726,066 13.4 751 6,789,984 11.1 3 (1–7)
60–69 2357 10,420,187 22.6 1246 5,344,994 23.3 1111 5,075,193 21.9 3 (1–7)
70–79 3094 6,931,652 44.6 1798 3,866,840 46.5 1296 3,064,812 42.3 4 (1–9)
80–89 2859 3,495,850 81.8 1914 2,252,297 85.0 945 1,243,553 76.0 6 (1–11)
≥90 563 617,841 91.1 415 467,360 88.8 148 150,481 98.4 5 (2–10)
Total 13,663 102,324,750 13.4 7823 51,713,460 15.1 5840 50,611,290 11.5 4 (1–8)
Age-
standardizedc
13.1 (12.9–13.3) 13.6 (13.3–13.9) 12.5 (12.2–12.9)
Abbreviations: HZ herpes zoster
aPer 100,000 person-years
bFor inpatient primary diagnoses only
cDirectly standardized to the age distribution in the 2000 Danish Census using the following weights: 0.13 for 0–9 years, 0.11 for 10–19 years, 0.14 for 20–29 years,
0.15 for 30–39 years, 0.14 for 40–49 years, 0.14 for 50–59 years, 0.09 for 60–69 years, 0.07 for 70–79 years, 0.03 for 80–89 years, and 0.01 for ≥90 years
Fig. 1 Rates of first-time hospital-based diagnoses of herpes zoster, Denmark, 1994–2012, directly standardized to the age-distribution in the 2000
Danish Census
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Fig. 2 Age-specific rates of hospital-based diagnoses of herpes zoster according to diagnosis types, Denmark, 1994–2012
Table 2 No. (%) of types of first-time hospital-based diagnoses of HZ, Denmark, 1994–2012
Calendar period Total
1994–1999 2000–2005 2006–2012
Type of hospital contact
Emergency room 765 (19) 655 (15) 610 (12) 2030 (15)
Outpatient clinic 911 (23) 1035 (24) 1459 (28) 3405 (25)
Inpatient 2323 (58) 2661 (61) 3244 (61) 8228 (60)
Type of diagnosis
Primary diagnosis 3040 (76) 3036 (70) 3759 (71) 9835 (72)
Secondary diagnosis 959 (24) 1315 (30) 1554 (29) 3828 (28)
Severity of HZ
Uncomplicated 2873 (72) 3178 (73) 3580 (67) 9631 (70)
Complicated 1126 (28) 1173 (27) 1733 (33) 4032 (30)
Extent of HZ
Localized 3390 (85) 3708 (85) 4235 (80) 11,333 (83)
Disseminated 609 (15) 643 (15) 1078 (20) 2330 (17)
Diagnosis code (ICD-10 code)
HZ meningo-encephalitis (B02.0–1) 62 (1.6) 79 (1.8) 196 (3.7) 337 (2.5)
HZ encephalitis (B02.0) 54 (1.4) 63 (1.4) 146 (2.7) 263 (1.9)
HZ meningitis (B02.1) 8 (0.20) 16 (0.37) 50 (0.94) 74 (0.54)
HZ with other nervous system involvement (B02.2) 323 (8.1) 320 (7.4) 418 (7.9) 1061 (7.8)
HZ ophthalmicus (B02.3) 517 (13) 530 (12) 655 (12) 1702 (12)
Disseminated HZ (B02.7) 74 (1.9) 90 (2.1) 109 (2.1) 273 (2.0)
HZ with other complication (B02.8) 150 (3.8) 154 (3.5) 355 (6.7) 659 (4.8)
HZ without complication (B02.9) 2873 (72) 3178 (73) 3580 (67) 9631 (71)
Total 3999 (29) 4351 (32) 5313 (39) 13,663 (100)
Abbreviations: HZ herpes zoster, ICD-10 International Classification of Diseases, 10th revision
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patients with inpatient and secondary HZ diagnoses
(Additional file 1: Table S3).
Mortality
The 30-day mortality for persons with HZ was 3 %, cor-
responding to 7 % (434/6059) of all deaths in the cohort
in total. We observed higher mortality in patients with
HZ compared with the general population (Table 4).
The overall SMR was 1.8 (95 % CI: 1.7–1.8): 1.6 (95 %
CI: 1.6–1.7) in women and 2.0 (95 % CI: 1.9–2.1) in
men. The highest SMRs were found in young patients.
However, after stratifying by comorbidity level, the SMR
was not increased in patients without comorbidity (SMR
1.0; 95 % CI: 0.9–1.0). SMRs according to subtypes of
HZ diagnoses are shown in Additional file 1: Table S4.
Discussion
In this nationwide Danish study, the rate of hospital-based
HZ diagnoses was stable at around 13 per 100,000
person-years over a study period of 19-years. The rate was
3–6 per 100,000 person-years for persons aged below
50 years, increasing by approximately twofold with each
consecutive decade of age. Thirty percent of patients had
complicated HZ and comorbidity was prevalent, particu-
larly diseases involving immune dysregulation.
The age-specific hospitalization rates from the present
study and previous European studies are shown in
Additional file 1: Figure S3. While the overall and age-
specific inpatient hospital diagnosis rates in Denmark
accord with previous studies [11–24], however there is
considerable variation across countries. This variation
may result from differences in hospital admission prac-
tices or health-seeking behavior, as the overall incidence
Table 3 Characteristics of 13,663 patients with a first-time
















Any of the comorbidities identified 8067 (59)




Very severe 2867 (21)
Comorbidities in the Charlson Comorbidity Index
Myocardial infarction 921 (6.7)
Congestive heart failure 1050 (7.7)
Peripheral vascular disease 803 (5.9)
Cerebrovascular disease 1446 (11)
Dementia 256 (1.9)
Chronic pulmonary disease 1911 (14)
Connective tissue disease 983 (7.2)
Ulcer disease 848 (6.2)
Mild liver disease 171 (1.3)
Diabetes without end-organ damage 918 (6.7)
Hemiplegia 57 (0.42)
Moderate to severe renal disease 643 (4.7)
Diabetes with end-organ damage 419 (3.1)
Non-metastatic solid tumor 1755 (13)
Leukemia 489 (3.6)
Lymphoma 834 (6.1)
Moderate to severe liver disease 62 (0.45)
Metastatic solid tumor 331 (2.4)
Acquired immune deficiency syndrome 153 (1.1)
Comorbidities associated with immune dysregulation 4942 (36)
Stem cell or bone marrow transplant 273 (2.0)
Solid organ transplant 152 (1.1)
Table 3 Characteristics of 13,663 patients with a first-time
hospital-based diagnosis of HZ, Denmark, 1994–2012
(Continued)
Human immunodeficiency virus infection 210 (1.5)
Primary immunodeficiency 61 (0.45)
Any cancer 2821 (21)
Any autoimmune disease 2293 (17)
Hematologic 73 (0.53)
Endocrine 614 (4.5)
Central nervous system 67 (0.49)
Gastrointestinal 274 (2.0)
Skin 315 (2.3)
Connective tissue disease 1080 (7.9)
Pulmonary 31 (0.23)
Ocular 94 (0.69)
Abbreviations: HZ herpes zoster
aOverall, the age range was 0 to 103 years. Median age was 68 years: 71 years
in women and 65 years in men
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rate in the general population varies only slightly across
Europe [2]. Nevertheless, the nearly exponential increase
in the rate of hospital-based HZ diagnoses after age
50 years [11–18, 20–23] and the female predominance
[12, 13, 16, 18, 19, 21] in our study are comparable with
results from the previous studies. However, none of
these studies presented data specifically on HZ diag-
nosed in hospital-based outpatient clinics, which
accounted for one-fourth of patients in our study.
We observed a shorter length of hospital stay (mean
6.2 days) compared to previous studies (mean 7.5 to
11.2 days) [12, 13, 17–19, 22, 25, 26]. Our result was
closest to that reported in a Swedish study [18], which
also had a similar diagnosis rate and proportion of
complicated infections. The shorter length of stay may
be explained by hospitalization of milder cases of HZ in
Denmark and Sweden, as the proportion of complicated
infections (mainly ocular and neurological) was approxi-
mately twice as high in Southern Europe [12, 14, 19, 20,
25, 26]. Studies from Southern Europe also reported a
higher prevalence of predisposing conditions, such as
HIV [12, 14, 16, 20], organ transplantation [12, 16], dia-
betes [16], and ‘blood dyscrasias and some immune defi-
ciencies’ [16] in HZ patients. Frequencies of malignancy
[14, 16, 20] and connective tissue disease [16] were com-
parable to the results in our study. Finally, the length of
stay for patients with neurological complications in our
data accords with Italian and French data [19, 25, 26],
further suggesting that differences in admission practices
play a role. The slight temporal increase in the diagnosis
rate of HZ encephalitis and meningitis in our study may
result from increased use of polymerase chain reaction
technology for detecting varicella-zoster virus in cere-
brospinal fluid [27].
Chronic pulmonary disease, connective tissue disease,
cancer, HIV, and solid organ transplantation were rela-
tively more frequent in our study compared with other
selected Danish patient populations [28–31]. This finding
is consistent with the increased risk of HZ in patients with
immune dysregulation due to either disease pathophysi-
ology or treatment (e.g., with glucocorticoids) [1]. Apart
from posing an additional burden to these patients, HZ
could complicate their treatment, for instance by delaying
chemotherapy for cancer. We lacked data on HZ treated
in general practice and had no comparison cohort, which
prevented us from examining whether HZ was associated
with increased mortality in patients with certain comor-
bidities. Although we found increased mortality among
patients with comorbidity, we obtained this result using
standardization to the entire general population, including
those without comorbidity. Thus, the increased SMRs
may potentially reflect excess mortality from the comorbid
condition rather than from an interaction between HZ
and the comorbid condition. The difference in SMRs by
age could also be explained by use of the general popula-
tion as reference. A high prevalence of the exposure
(HZ) in the general population would bias the SMR
towards the null [32]. Because the prevalence of HZ
increases with age, the risk of this bias also may
increase with age, potentially explaining our finding
of lower SMRs in the oldest age groups.
We used a comprehensive nationwide database to study
hospital-based HZ diagnoses within a universal healthcare
system, which limits selective inclusion of specific hospitals,
insurance groups, or age groups. Nonetheless, our study
has some limitations. Since 2002, reimbursements to public
and private hospitals have been administered using the
Diagnosis Related Group (DRG) system in the DNPR [6],
Table 4 SMRs among patients with a first-time hospital-based
diagnosis of HZ, Denmark, 1994–2012
Observed Expected SMR (95 % CI)a
Overall 6059 3414 1.8 (1.7–1.8)
Age group (years)
0–9 12 1.1 10.7 (6.1–18.9)
10–19 18 1.1 16.4 (10.4–26.1)
20–29 34 4.0 8.5 (6.1–12.0)
30–39 66 11 5.8 (4.6–7.4)
40–49 143 30 4.8 (4.1–5.7)
50–59 451 124 3.6 (3.3–4.0)
60–69 916 350 2.6 (2.5–2.8)
70–79 1874 988 1.9 (1.8–2.0)
80–89 2080 1507 1.4 (1.3–1.4)
≥ 90 465 397 1.2 (1.1–1.3)
Sex
Women 3530 2166 1.6 (1.6–1.7)
Men 2529 1248 2.0 (1.9–2.1)
Charlson Comorbidity Index level
None 1663 1651 1.0 (1.0–1.1)
Moderate 1229 784 1.6 (1.5–1.7)
Severe 1346 506 2.7 (2.5–2.8)
Very severe 1821 473 3.8 (3.7–4.0)
Comorbidity associated with
immune dysregulation
No 3378 2513 1.3 (1.3–1.4)
Yes 2681 901 3.0 (2.9–3.1)
Any of the identified
comorbidities
No 1532 1555 1.0 (0.9–1.0)
Yes 4527 1858 2.4 (2.4–2.5)
Abbreviations: CI confidence interval, HZ herpes zoster, SMR Standardized
mortality ratios
aComputed using indirect standardization with the Danish general population
as reference. Due to rounding the estimates and upper and lower confidence
bounds may appear the same
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which may have affected physicians’ choice of primary and
secondary diagnosis codes. As well, the completeness and
validity of HZ diagnoses in the DNPR is unknown. Still,
other studies have found high diagnostic accuracy with
positive predictive values ranging from 72 to 100 %
[33–37]. Although there is a specific code for specifying
consultation with post-herpetic neuralgia (ICD-10 G53.0),
it is possible that some codes, particularly ‘other nervous
system involvement’, were assigned alone to patients who
had this chronic complication rather than acute HZ.
However, we consider such misclassification of minor
importance because these patients experienced recent
varicella-zoster virus reactivation.
Our comorbidity assessment has some limitations. The
positive predictive value for diagnoses included in the
CCI are known to vary depending on the disease, depart-
ment of origin, and reference standard [6]. Moreover,
incompleteness is expected for conditions that are
treated primarily in general practice, e.g., diabetes. An-
other concern is underestimation early in the study
period due to left-censoring of outpatient and emer-
gency room diagnoses before 1994. Similarly, changes in
coding when new medical treatments are introduced
may explain the lack of HZ patients with bone marrow
transplantations early in the study period.
The majority of patients with HZ in Denmark are treated
in general practices [38], which are not subject to system-
atic monitoring in national registries. Thus, analysis of
temporal trends in our study may not reflect true changes
in disease incidence in the population. Administrative fac-
tors (e.g., changing admission practices) are also important
in determining whether patients receive a hospital-based
diagnosis. As well, the lack of primary care data may have
caused underestimation of the SMRs [32].
Conclusions
This nationwide Danish study provided pre-vaccination
estimates of the epidemiology of hospital-based HZ.
Because hospital-based treatment is likely linked to
presence of complications or underlying diseases, our
study likely comprises the most severe cases of HZ.
Indeed, 30 % of patients had complicated HZ and dis-
eases associated with increased risk of severe HZ (e.g.,
hematological cancer [3, 4]) were prevalent. These re-
sults stress the importance of considering hospital-based
diagnoses in studies assessing the overall burden of HZ
in the population.
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